76 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
Exhibit 99.1
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
Brian McVeigh as Chief Business Officer
BOSTON, Mass., May 30 … and investment management to Zafgen’s executive leadership team.
“Brian is an accomplished executive and adds significant value to our executive
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 Sep 15
Zafgen Announces Transition of Board of Directors
12:00am
Exhibit 99.1
Zafgen Announces Transition of Board of Directors
-Adds Significant Industry Leadership Experience-
BOSTON – September 28, 2015 … Officer of Cubist Pharmaceuticals, and brings over 28 years of experience from various leadership and senior management positions in the life sciences
8-K
LRMR
Larimar Therapeutics Inc
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
School’s Management Development Program. Dr. Barrett’s qualifications to sit on the Board include his extensive leadership, executive, managerial … leadership roles at global biopharmaceutical companies Celgene Corporation and Amgen.
Thomas Edward Hamilton(Age 53). Mr. Hamilton has served as a member
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am
leveraged its leadership position in MetAP2 biology, together with new insights into the pathway, to deliver a diverse portfolio of highly-differentiated … strategic, operational and scientific leadership to drive those programs forward and further realize the broad potential of this platform,” commented Dr
8-K
EX-99.1
s1uoaoqjwebux
5 Feb 20
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
szpz2kczd2e5vipk3
6 Aug 20
Departure of Directors or Certain Officers
9:00am
8-K
EX-99.2
t1ktupxjkkqm2lpa6
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-99.2
s736f4 olgdsn
18 Dec 19
Additional proxy soliciting materials
8:11am
8-K
EX-99.1
oxvmt
13 Jan 20
Regulation FD Disclosure
7:17am
8-K
EX-99.2
aot4arr
11 Aug 20
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
7:38am
DEFA14A
EX-99.1
8h6e4f33wwf
13 Jan 20
Additional proxy soliciting materials
7:15am
8-K
EX-99.1
drltijhnssn
3 Jun 20
Regulation FD Disclosure
12:00am
8-K
5j0jzcnct8s
30 Sep 15
Zafgen Announces Transition of Board of Directors
12:00am
8-K
EX-99.1
7ks15s0gha2x6an
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
PRE 14A
5ifeoag0d
12 Apr 24
Preliminary proxy
6:06am